ROCHE HOLDING AG

Roche boosts its oncology lineup with a $1.53B deal for Simcere’s tri‑specific antibody SIM0660, adding a potent CD79a/CD19/CD3 therapy to its antibody‑drug conjugate portfolio and partnering on TLN‑121 for lymphoma. This strategic move positions Ro…

Roche’s $750 million U.S. plant expansion in Oregon doubles Genentech’s drug‑manufacturing capacity, while a CHF 410 million bond fuels global R&D and growth plans.

Roche expands its drug pipeline and precision medicine focus through AI‑driven discovery, breast‑cancer combo trials, oncology regulatory studies and biomarker validation partnerships.

Roche’s 1H 2026 results show a 6 % currency‑neutral revenue rise amid a strong Swiss franc, reaffirming UBS’s Buy rating and highlighting resilient core growth and a robust oncology pipeline.

Roche’s Tecentriq gets FDA approval for adjuvant muscle‑invasive bladder cancer, boosting its oncology pipeline and share value through precision ctDNA‑guided therapy.

Roche Holding AG faces political, legal, and competitive pressures that threaten its pricing power and employee compliance, prompting a dual strategy of regulatory engagement and operational excellence to safeguard its global pharmaceutical dominanc…

Roche Holding AG faces a turbulent day: new respiratory diagnostics promise growth, but recent therapeutic failures and hefty research spend cast doubt on future earnings.

Roche Holding AG shifts focus: stops SMA trials for its anti‑myostatin antibody, yet keeps exploring muscle‑growth in obesity, boosting its weight‑loss strategy.

Roche’s new Head of Pharma Research, Dr. Mark Dawson, powers a breakthrough Phase‑III win for Gazyva in kidney disease, positioning Roche for growth in rare‑disease therapy.

Roche Holding AG’s growth, oncology dominance, and new lupus drug are weighed against legal risks and pricing pressures—investors must track how it turns opportunity into lasting profit.